[
  {
    "ts": null,
    "headline": "Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'",
    "summary": "Zevra Therapeutics stock crashed Wednesday in what one analyst called an \"overreaction\" to issues surrounding its acquired drug, Olpruva.",
    "url": "https://finnhub.io/api/news?id=9bd389ae09f4f507170b6cc9a5b88b2573812e000301cf90f1c15d95910ddc69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755111156,
      "headline": "Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'",
      "id": 136339705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Zevra Therapeutics stock crashed Wednesday in what one analyst called an \"overreaction\" to issues surrounding its acquired drug, Olpruva.",
      "url": "https://finnhub.io/api/news?id=9bd389ae09f4f507170b6cc9a5b88b2573812e000301cf90f1c15d95910ddc69"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3da74462b902f05a1b464f654d9c719c85654678636b9a3c6ee84c15ec7c3059",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755102900,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 136354074,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3da74462b902f05a1b464f654d9c719c85654678636b9a3c6ee84c15ec7c3059"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
    "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
    "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755091980,
      "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
      "id": 136328328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
      "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call",
    "summary": "Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its portfolio and notable volume growth, particularly in general medicine, rare diseases, and oncology. CEO Robert Bradway highlighted that 15 products achieved double-digit sales growth, attributing momentum to broad-based execution and continued expansion in both established and emerging therapeutic areas. However, despite these operational highlights, management acknowledged the o",
    "url": "https://finnhub.io/api/news?id=608df5bb49678c3692311fca7ecf98451b9712f6bc1593da7861b971ed77aaf4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057548,
      "headline": "5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call",
      "id": 136328394,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its portfolio and notable volume growth, particularly in general medicine, rare diseases, and oncology. CEO Robert Bradway highlighted that 15 products achieved double-digit sales growth, attributing momentum to broad-based execution and continued expansion in both established and emerging therapeutic areas. However, despite these operational highlights, management acknowledged the o",
      "url": "https://finnhub.io/api/news?id=608df5bb49678c3692311fca7ecf98451b9712f6bc1593da7861b971ed77aaf4"
    }
  },
  {
    "ts": null,
    "headline": "AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism",
    "summary": "Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to $9.18 billion. The company’s full-year revenue guidance of $35.5 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $6.02 per share was 14.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=5ff4ced6c820f72acbd33083d5af4b407adabc123186c90542c1a490f56e9772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755056619,
      "headline": "AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism",
      "id": 136328395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to $9.18 billion. The company’s full-year revenue guidance of $35.5 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $6.02 per share was 14.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=5ff4ced6c820f72acbd33083d5af4b407adabc123186c90542c1a490f56e9772"
    }
  }
]